Introduction
Pancreatic cancer is predicted to become the second leading cause of cancer-related death in the United States and Germany by 2030 [1] . Even with the intensified treatment regimens FOLFIRINOX and gemcitabine plus nab-paclitaxel, prognosis of advanced pancreatic cancer patients remains poor with a median overall survival of less than 1 year. A major obstacle in developing innovative treatment approaches for patients with advanced pancreatic cancer is the paucity of reliable prognostic and predictive biomarkers [2] . The only (blood based) biomarker recommended for routine clinical use by the (recently updated) National Comprehensive Cancer Network (NCCN)-guideline is carbohydrate antigen [3] . Originally described in 1979 by Koprowski et al., CA 19-9 is a well-established indicator for prognosis of advanced pancreatic cancer patients. Yet, levels of CA 19-9 can be considerably altered by inflammation, cholangitis or biliary obstruction-conditions frequently observed in patients with advanced pancreatic cancer undergoing palliative chemotherapy. Further there is no consensus on the utility of CA 19-9 as a reliable marker to assess treatment response in patients undergoing palliative chemotherapy [4] [5] [6] .
A promising, rather new tool to assess tumor response in advanced pancreatic cancer patients is the measurement of circulating tumor DNA (ctDNA) in plasma samples. The determination of ctDNA is considerably facilitated by the genetic homogeneity of pancreatic cancer and a high frequency (about 85%-95%) of oncogenic point mutations in the Kirsten rat sarcoma virus (KRAS)-gene [7] . To date, only small pilot studies have addressed the clinical value of serial mut KRAS ctDNAmeasurements in pancreatic cancer [7] [8] [9] [10] . In the present study, the BEAMing technology was used for serial mut KRAS ctDNA measurements: absolute levels and kinetics during chemotherapy of mut KRAS ctDNA, CA 19-9, carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) were correlated with radiological response, progression-free and overall survival times.
The objective of this explorative biomarker study was to address the following questions: do pre-therapeutic levels or early changes in mut KRAS ctDNA levels predict treatment response (in terms of radiological response) in patients with advanced pancreatic cancer receiving chemotherapy? What are optimal time points for determination of mut KRAS ctDNA? What is the potential of mut KRAS ctDNA in detecting progressive disease (PD)-especially in comparison to established protein based tumor markers?
Materials and methods

Patient population and treatment
The detailed study design of this biomarker study, including details on decision on treatment regimens, duration of therapy and tumor response evaluation has been published previously [11] . In brief, consecutive patients with histologically or cytologically confirmed advanced pancreatic cancer (locally advanced or metastatic disease) undergoing palliative treatment at our high-volume comprehensive cancer center were prospectively included between May 2006 and April 2010. Tumor assessment was carried out using computed tomography or magnetic resonance imaging according to standard response evaluation criteria in solid tumors (RECIST; version 1.1) every 8-12 weeks. The study was approved by the local ethics committee of Ludwig-Maximilians-University of Munich (project number 093-02) and all patients gave written informed consent for the collection of blood and data analysis. This report was written according to the most recent REporting recommendations for tumor MARKer prognostic studies (REMARK) [12] .
Blood sampling, mut KRAS and tumor marker analysis For ctDNA analyses, plasma samples were collected before initiation of chemotherapy (day 0) and thereafter weekly during the first 2 months of chemotherapy (until day 56). Additional samples were obtained at time of radiological staging and during subsequent treatment. In selected patients close-meshed blood sampling during the first week(s) of therapy was carried out. BEAMing for detection of mut KRAS ctDNA as well as pyrosequencing for detection of mut KRAS in tumor tissue samples were carried out as described previously [13, 14] . Venous blood samples were centrifuged for 15 min at 3000g within 2 h of venipuncture. Sera and plasma samples were separated manually, aliquoted into microtubes and without any further treatment frozen at À80 C. Serum levels of CA 19-9, CEA and CYFRA-21-1 were already determined for the previously reported tumor marker study [11] ; additional measurements for the current study were carried out at the central laboratory of LMU university hospital. All assays were carried out blinded to study end points.
Statistical analyses
To evaluate the response prediction, patients were divided into two groups according to their response to therapy: patients with (complete or partial) remission and stable disease were combined into the 'Non-PD' group in contrast to patients who suffered from 'PD'. Wilcoxon-MannWhitney test was used to test for significance between marker levels in therapy response groups and differences in lead time for detection of PD, respectively. Fisher's exact test was used to test for statistical significance of mut KRAS ctDNA normalization in the non-PD versus PD group. Chisquare test was used to test for significant differences in sensitivity and specificity of mut KRAS ctDNA compared with the respective proteinbased tumor markers in detection of PD. Overall and progression-free survival were calculated as time from therapy initiation to death (from any cause) or radiological evidence of PD, respectively. Quartile levels of mut KRAS ctDNA for the respective tumor markers were used to divide patients into four equal groups. Differences in overall and progressionfree survival were calculated using the log-rank test. Because of the exploratory nature of the analysis no hypotheses were defined before study initiation. Further, adjustment for multiplicity of testing was not applied. Statistical analyses were carried out using SAS version 9.4 (SAS Institute, Cary, NC) and Graphpad Prism 7.01 (GraphPad Software Inc, La Jolla, CA). A P value of 0.05 or lower was considered statistically significant.
Results
Patient characteristics
For the previously described biomarker study 83 patient were consented [11] . Of those patients, plasma samples were available for 54 patients (for detailed patient characteristics see Table 1 ). In total 284 blood samples were analyzed for the present biomarker study. At the time of final analysis all patients had died.
Tissue KRAS mutations and mut KRAS ctDNA
Tissue samples to screen for the presence of mut KRAS within tumor tissue were available for 39 patients ( Table 2 ). The majority of patients (n ¼ 32/39, 82%) had a detectable tissue KRAS mutation. Of the 32 patients with mut KRAS positive tumors, detectable amounts of mut KRAS ctDNA were present in 24 cases (detection rate of 75%). If only patients with metastatic disease were considered, detection rate was slightly higher (n ¼ 22/28, 79%). Two different ctDNA KRAS mutations could be detected in two patients. At time of diagnosis mut detected in none of the patients with KRAS wild-type tumors; however, one patient with a tissue KRAS wild-type tumor developed detectable amounts of mut KRAS ctDNA while undergoing palliative chemotherapy (Table 2) .
Prognostic relevance of pre-therapeutic mut KRAS, CA 19-9, CEA and CYFRA 21-1
Of the 54 patients included in this biomarker study, a plasma sample collected within 30 days before initiation of palliative first-line chemotherapy was available for 51 patients. To test for the prognostic relevance of mut KRAS (in tissue and ctDNA), CA 19-9, CEA and CYFRA 21-1, overall survival and progressionfree survival times were calculated according to the presence of mut KRAS in tissue or plasma-and serum levels of CA 19-9, CEA and CYFRA 21-1, respectively. mut KRAS in plasma but not in tumor tissue samples was significantly correlated to adverse progression-free survival and overall survival from start of palliative chemotherapy (supplementary Figure S1A and B, available at Annals of Oncology online).
mut KRAS ctDNA, CA 19-9 and CYFRA 21-1 were all able to identify different prognostic groups of advanced pancreatic cancer patients (regarding overall survival and progression-free survival), while results for CEA were only significant for progression-free survival (supplementary Figure  S1A and B, available at Annals of Oncology online).
Radiological response prediction by kinetics of mut KRAS ctDNA, CA 19-9, CEA and CYFRA 21-1
To test for the potential of absolute mut KRAS ctDNA, CA 19-9, CEA and CYFRA 21-1 levels as predictive markers for (radiological) response to the first-line chemotherapy in patients with advanced pancreatic cancer, patients were grouped into patients with non-PD or PD upon first radiological staging. As shown in supplementary Figure S2 , available at Annals of Oncology online, absolute levels of mut KRAS ctDNA as well as absolute levels for the protein-based tumor markers significantly differed between non-PD and PD patients at time of therapy initiation and first staging. Additionally, absolute levels at different time points (day 0, 7, 14, 28 of chemotherapy and time of staging) were significantly different between non-PD and PD patients at most time points for mut KRAS ctDNA and the three serum tumor markers, respectively (Table 3) .
Detailed kinetics for mut KRAS ctDNA during the first-line chemotherapy are summarized in Figure 1A and B. When compared with the kinetics of the established tumor markers (supplementary Figure S3A and B, available at Annals of Oncology online), absolute as well as relative changes in mut KRAS ctDNA Original article Annals of Oncology levels were more pronounced and rapid than changes in tumor marker levels. In order to evaluate the clinical value of kinetics of mut KRAS ctDNA as well as tumor markers as early predictor of therapy response (non-PD versus PD), we calculated differences from baseline for different time points (day 0, 7, 14, 21, 28 and day of staging) (Table 3) . Overall, kinetics of mut KRAS ctDNA were statistically significant for two time intervals (and closely failing statistical significance for an additional time interval) while CA 19-9 kinetics were only meaningful for one time interval (day 0 to day of first staging) ( Table 3) . Regarding kinetics during the first month of chemotherapy, a significant correlation between kinetics from d0 to d14 for mut KRAS ctDNA and therapy response was found. No statistically significant correlation for early kinetics of the protein-based tumor markers was found during the first month of therapy.
For two patients, close meshed measurements at the beginning of chemotherapeutic first-line treatment were available ( Figure 1C) . In both patients a very early increase of mut KRAS ctDNA at days 1 and 2 was followed by a decrease of mut KRAS ctDNA. This decrease of mut KRAS ctDNA after the first 7-14 days of chemotherapy was seen in most patients ( Figure 1A and B) . Of interest, it was notably pronounced (hereafter termed mut KRAS ctDNA normalization) in the majority of patients without disease progression at time of first radiological staging (non-PD group). Although a small number of patients with mut KRAS ctDNA normalization had disease progression at time of first radiological staging (PD), the proportion of patients with mut KRAS ctDNA normalization was significantly higher in the non-PD group ( Figure 2B ). Of interest, two patients without mut KRAS ctDNA normalization and missing evidence of PD upon first staging (pat. 12 and pat. 50) had evidence of PD early after first staging (PD 42 and 28 days after first staging, respectively).
Performance of mut KRAS ctDNA in detecting PD
The performance of mut KRAS ctDNA, CA 19-9 and CEA in detecting PD was assessed by serial blood sampling until disease progression. A total of 30 patients had serial blood samples drawn up until radiological evidence of PD (blood sample drawn at or a maximum of 30 days before radiological staging, for details see supplementary Methods, available at Annals of Oncology online); Table 3 . Correlation of median absolute biomarker levels (T x ) and marker kinetics (T x 2 T 0 , %) with objective response to chemotherapy
Stable disease and remission (non-PD)
Progressive disease (PD) P value Figure 1 . Kinetics of mut KRAS ctDNA during therapy. *Patient 12 and patient 50 had evidence of progressive disease shortly after the first radiological staging (42 and 28 days after first staging, respectively). (A) Absolute levels of mut KRAS ctDNA during chemotherapy for patients with progressive disease (PD) versus patients with partial response or stable disease (non-PD) upon first radiological staging. Only patients with two or more measurements during chemotherapy were included. (B) Top: Relative levels of mut KRAS ctDNA during chemotherapy: Absolute levels of mut KRAS ctDNA during chemotherapy were normalized to the respective pretreatment levels ( mut KRAS ctDNA ¼ 1) for each individual patient with PD versus partial response or stable disease (non-PD) upon first radiological staging. Patients without measurable mut KRAS ctDNA at baseline (non-PD: n ¼ 16, PD: n ¼ 3) or less than two measurements at the defined time points after initiation of chemotherapy had to be excluded (PD: n ¼ 1, [Pat. 52]). Bottom: Non-PD versus PD patients with mut KRAS ctDNA normalization (conversion from mut KRAS ctDNA positivity to negativity). Fisher's exact test was used to test for statistical significance between the two groups. (C) Absolute levels of mut KRAS ctDNA for two patients with close meshed measurements early during chemotherapy.
29 of these patients received palliative first-line treatment. In four patients, additional blood samples were acquired during the second-line chemotherapy. In one patient, blood samples were only acquired during the second-line chemotherapy. Of the 30 eligible patients, two patients had to be excluded because of very early disease progression (days 7 and 9, respectively). CYFRA 21-1 was not included in this analysis as there were less than 10 patients with available CYFRA 21-1 levels at or before the time of PD. For the sensitivity and specificity analyses, any increase in mut KRAS ctDNA, an increase of more !1 ng/ml for CEA and the Figure 2 . Sensitivity, specificity and lead time of mut KRAS ctDNA, CA 19-9 and CEA in detecting progressive disease. (A and B) For mut KRAS ctDNA any increase from base-line during chemotherapy was considered meaningful; for CEA any increase >1 ng/ml from baseline was considered meaningful; for CA 19-9 different cut-off values were tested as indicated. Chi-square test was used to test for statistical significance between mut KRAS ctDNA and CEA or the different cut-off values for CA 19-9, respectively. (C) Lead time from diagnosis of progressive disease by mut KRAS ctDNA or different cut-off values for CA 19-9 to radiological diagnosis of progressive disease. Mann-Whitney test was used to test for statistical significance between mut KRAS ctDNA or the different cut-off values for CA 19-9, respectively.
specified criteria for CA 19-9 given in Figure 2A and B were considered meaningful. Increases in mut KRAS ctDNA indicated PD with a sensitivity of 83% (n ¼ 20/24, Figure 2A) ; importantly, in our cohort, no false-positive increases for mut KRAS ctDNA were observed (specificity 100%, Figure 2B ). To the best of our knowledge, no established cut-off criteria for a 'meaningful increase' in CA 19-9 exist. We therefore tested sensitivity and specificity of CA 19-9 for different cut-off criteria. As depicted in Figure 2A and B, sensitivity and specificity for CA 19-9 highly depended upon the applied cut-off criteria.
mut KRAS ctDNA was (statistically significant) superior to CA 19-9 in either sensitivity or specificity for 4/6 of the applied criteria. As CEA was significantly inferior to mut KRAS ctDNA in sensitivity even for the low threshold defined above, no further cut-off criteria were tested. To evaluate the lead-time of mut KRAS ctDNA and CA 19-9 in detecting PD, differences between first marker increase and radiological evidence of PD were compared. No difference was observed for lead time of mut KRAS ctDNA and CA 19-9 to radiological evidence of PD ( Figure 2C ).
Discussion
The current biomarker study was able to detect mut KRAS ctDNA in 75% of all pancreatic cancer patients with confirmed tissue KRAS mutations. Remarkably, we observed the appearance of a second KRAS mutation during therapy in two patients and the appearance of mut KRAS ctDNA during therapy in one patient without mut KRAS in ctDNA or tissue at treatment initiation. Our group previously reported about a patient with a newly diagnosed tissue KRAS mutation in advanced pancreatic cancer during systemic treatment [15] . Together, these findings highlight the importance of genetic reassessment (especially within clinical trials targeting KRAS) in pancreatic cancer and suggest significant genetic heterogeneity, either intratumoral or between tumor/different metastatic sites.
As shown previously, our study confirms the prognostic significance of mut KRAS ctDNA in (advanced) pancreatic cancer. Yet, to the best of our knowledge, only limited data on the kinetics of ctDNA in advanced cancers in general and advanced pancreatic cancer in particular are available to date (for pancreatic cancer, we identified only one study that carried out serial measurements in more than 15 patients) [16] . We witnessed rapid changes of mut KRAS ctDNA levels early during therapy. Importantly, these changes were an early indicator of response to therapy, indicating later radiological response already at day 14 of therapy and showing superiority over CA 19-9 (in terms of lead time) and CEA or CYFRA 21-1 (no response prediction by kinetics during therapy). Early information on response to therapy might be of great clinical utility and could lead to novel treatment concepts. Two important factors in developing such concepts are adequate timing and cut-off values: our results indicate that an initial increase (i.e. during the first 7 days of therapy) is commonly observed in most patients, while an increase at or after day 14 indicates later disease progression in almost all patients. Day 14 might therefore be a reasonable time point to evaluate early kinetics. Regarding cut-off values, mut KRAS ctDNA normalization (i.e. conversion from mut KRAS ctDNA positivity to negativity) could be a sensitive and specific cutoff value and should be evaluated in further studies. Small pilot studies investigating ctDNA for therapy monitoring in resectable (8 patients) and advanced pancreatic cancer (13 patients) yielded promising results [7, 8] . To the best of our knowledge, we are the first to evaluate ( mut KRAS) ctDNA in therapy surveillance of a larger proportion of (advanced) pancreatic cancer patients, and even more importantly in comparison to already established protein-based tumor markers. In our cohort, mut KRAS ctDNA was a sensitive and highly specific marker of disease progression. The astonishingly high specificity (100%) of mut KRAS ctDNA is in line with the high specificity of mut KRAS ctDNA in other settings (e.g. resectable pancreatic cancers patients, colorectal cancer patients) [17, 18] . While a direct comparison between CA 19-9 and mut KRAS ctDNA is difficult due to the absence of established CA 19-9 cut-off values in therapy surveillance, our results suggest that mut KRAS ctDNA might be superior to CA 19-9 and CEA (in terms of sensitivity and specificity) in therapy surveillance of advanced pancreatic cancer patients who are mut KRAS ctDNA positive at time of therapy initiation.
Our study has several important limitations: the relatively small number of patients included in our study, the explorative study design and a missing validation cohort.
In conclusion, our results suggest that repeated mut KRAS ctDNA measurements might be a promising tool for early response prediction and therapy surveillance in patients with advanced pancreatic cancer. Of note, these results must be confirmed by larger prospective clinical trials on sequential mut KRAS ctDNA measurements. As recently suggested in a joint review from ASCO and the College of American Pathologists, these studies should also evaluate the clinical benefit of serial mut KRAS ctDNA testing (e.g. does early response prediction or therapy monitoring by mut KRAS ctDNA translate into a survival benefit for advance pancreatic cancer patients) [19] .
